<p><em>Expert Perspectives</em>^® delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medicine, in a concise and timely format. <em>Expert Perspectives</em>^®<em> in HR+/HER2- Early Breast Cancer </em>will feature community-selected experts and topics that we hope you will find of value in your clinical practice.</p> <div class="bodytext_module_container"> <div class="bodytext_module_body"> <hr /> <p><strong>VIEW THE TOPICS:</strong></p> <p><br></p> </div> </div> <div class="bodytext_module_container"> <div class="bodytext_module_body"> <p><strong><span style="color: #2f6a81;">Patient Care Perspectives</span></strong></p> <ul> <li>Multidisciplinary Management of Patients With Early-Stage HR+/HER2- Breast Cancer</li> <li>Surveillance Expectations for Early-Stage Breast Cancer</li> <li>Symptom Clusters That Matter to Patients With Early-Stage HR+/HER2- Breast Cancer</li> </ul> <p><br></p> <p><strong><span style="color: #2f6a81;">Clinical Topic Updates</span></strong></p> <ul> <li>Adjuvant CDK4/6 Inhibitors: Who Should Get Them and How to Manage Them</li> <li>Multigene Assays and the Management of Early-Stage HR+/HER2- Breast Cancer</li> <li>Risk Assessment and Reduction Strategies for Early-Stage HR+/HER2- Breast Cancer</li> </ul> <p><br></p> <p><strong><span style="color: #2f6a81;">Expert Roundtables</span></strong></p> <ul> <li>Expert Roundtable Podcast: Managing Endocrine Therapy-Related Side Effects and Adherence</li> <li>Neoadjuvant Therapy for HR+/HER2- Breast Cancer</li> </ul> </div> </div>